First-Line Treatment for Hypertension with Elevated BNP

Treatment Algorithm Based on Heart Failure Status

The American College of Cardiology recommends initiating an ACE inhibitor or ARB combined with a diuretic as first-line therapy for patients with hypertension and elevated BNP, targeting a blood pressure <130/80 mmHg 1, 2
For patients with HFrEF, the American College of Cardiology suggests starting with guideline-directed medical therapy (GDMT) that simultaneously treats both hypertension and heart failure, including ACE inhibitors, ARBs, ARNIs, mineralocorticoid receptor antagonists, diuretics, and GDMT beta-blockers 1, 2
The American Heart Association recommends adding a diuretic to control volume overload and achieve blood pressure targets in patients with HFrEF 1, 2
The American College of Cardiology suggests targeting systolic BP <130 mmHg based on extrapolation from the SPRINT trial, though this specific target has not been tested in randomized trials of HFrEF patients 1, 2
The European Society of Cardiology recommends avoiding non-dihydropyridine calcium channel blockers as they have myocardial depressant activity and worsen outcomes in HFrEF 1, 2

The American Diabetes Association notes that ACE inhibitors have superior cardiovascular outcomes compared to other antihypertensive classes in high-risk patients with or without hypertension 3
The American College of Cardiology recommends using thiazide-like diuretics, such as chlorthalidone, as they have the strongest evidence for reducing heart failure events compared to other antihypertensive classes 2
The European Heart Journal suggests that combination therapy with RAS blockers plus diuretics is recommended as initial therapy for most patients with confirmed hypertension 5

The American Heart Association recommends starting with an ACE inhibitor, such as lisinopril 10 mg daily, and adding a thiazide-like diuretic, such as chlorthalidone 12.5-25 mg daily 7, 5
The European Society of Cardiology suggests monitoring renal function and potassium within 1-2 weeks of initiation 3
The European Heart Journal recommends escalating to triple therapy, including a RAS blocker, dihydropyridine calcium channel blocker, and thiazide/thiazide-like diuretic, if two-drug combination is inadequate 5
The American College of Cardiology suggests adding spironolactone 25 mg daily after confirming normal potassium and adequate renal function if triple therapy is inadequate 5

The American Heart Association warns against combining ACE inhibitor + ARB + renin inhibitor as this is potentially harmful 7
The European Society of Cardiology notes that beta-blockers alone are not first-line for uncomplicated hypertension but should be added when there are compelling indications 5
The European Heart Journal recommends targeting BP achievement within 3 months to maintain patient confidence and reduce cardiovascular risk 5